Skip to main content

25-03-2019 | Oncology | Main feed | News


FDA approves atezolizumab for extensive-stage SCLC

medwireNews: The PD-L1 inhibitor atezolizumab has been approved in the USA as a first-line treatment for patients with extensive-stage small-cell lung cancer (SCLC) and should be given in combination with carboplatin and etoposide. 

The approval follows results from the IMpower133 trial showing a significant improvement in overall and progression-free survival for atezolizumab plus carboplatin and etoposide compared with chemotherapy alone.

The recommended dose of atezolizumab is 1200 mg every 3 weeks initially given in a 60-minute infusion, with a 30-minute infusion permitted thereafter. If administered on the same day, chemotherapy should be given after atezolizumab treatment.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

See also: